"Spectranetics is a great company with innovative technology and a team of more than 400 employees who are committed to delivering safe and efficacious products to our customers and their patients," said Mr. Geisenheimer. "We are focused on moving forward and delivering the superior technology and service that has set Spectranetics apart since first bringing our products to market more than 15 years ago. Our rapid growth over the last several years demonstrates that our customers have confidence in our company, our people and our products. We appreciate their continued support."

Mr. Geisenheimer continued, "We appreciate John Schulte's contributions in helping our technology gain acceptance as an important treatment option for patients with peripheral arterial disease and as the premier treatment for lead management. We also have an understanding of the challenges before us, and the Board of Directors and I are confident that we are taking an important step towards putting these challenges behind us so that we can build a stronger future for our company."

As announced on September 4, 2008, Spectranetics was jointly served by the Food and Drug Administration and Immigration and Customs Enforcement with a search warrant requesting certain information and correspondence relating to the Company. The Company also previously announced that it is vigorously defending several securities lawsuits, purporting to be class actions, that have been filed against the Company and certain of its officers and directors, and that it has received a request from the Denver office of the Securities and Exchange Commission for the voluntary production of certain documents. The Company has also been named as a nominal defendant in a shareholder derivative suit against a number of its officers and directors. There can be no assurance that these matters will not lead to actions adverse to the Company. The Company is continuing to cooperate fully with the appropriate authorities and is working towards resolution of these matters. Spectranetics continues to expect that business operations will continue in the ordinary course.

Mr. Geisenheimer added, "As we continue to cooperate fully with the appropriate regulatory authorities, we are committed to ensuring the highest standards of business ethics and regulatory compliance at Spectranetics both now and into the future."

Executive Biography

Emile J. Geisenheimer has served as a Director of the Company since April 1990 and was appointed Chairman of the Board in June 1996. He was appointed Acting President and Chief Executive Officer of Spectranetics in May 2002 and served in this role through January 2003.

Mr. Geisenheimer is the founder and President of Madison Investment Partners, Inc., a private equity investment firm, and serves as a General Partner of each of its investment partnerships. Prior to forming Madison Investment Partners, he was general partner of Nazem and Company, a venture capital management firm, where he was responsible for developing the health care and medical device practices. Prior to joining Nazem and Company, Mr. Geisenheimer served in a number of senior executive positions with North American Philips Corporation (now Philips Electronics), including as President and CEO of Philips Electronic Instruments, Inc. and as a top marketing executive of Philips Medical Systems Inc.

Mr. Geisenheimer received an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S., cum laude in Economics, from Louisiana State University. Mr. Geisenheimer served in the U.S. Air Force in Southeast Asia.

2008 Third Quarter Financial Results Conference Call

Spectranetics will release 2008 third quarter financial results prior to market open on Wednesday, October 29, 2008. Company management will host an investment-community conference call beginning at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time) on Wednesday, October 29 to discuss those results and to answer questions. Dial-in information for the conference call and associated webcast will be announced at a later date.

About Spectranetics

Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company's disposable catheters use high-energy "cool" ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information visit www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include adverse results of the FDA and Immigration and Customs Enforcement investigation, adverse results of the SEC investigation or any securities litigation referenced above in which the Company or any of its officers or directors is a party, market acceptance of excimer laser atherectomy technology, increasing price and product competition, increased pressure on expense levels resulting from expanded sales, marketing, product development and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, market acceptance of new products or applications, product defects, ability to manufacture sufficient volumes to fulfill customer demand, availability of vendor-sourced components at reasonable prices, unexpected delays or costs associated with the Company's relocation and consolidation of its headquarters and manufacturing operations, and price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Spectranetics Corporation

COMPANY CONTACTS: 
Spectranetics Corporation 
Guy Childs, Chief Financial Officer 
719-633-8333 
or 
INVESTOR CONTACTS: 
Lippert/Heilshorn & Associates, Inc. 
Don Markley or Bruce Voss 
310-691-7100 
dmarkley@lhai.com 
or 
MEDIA CONTACTS: 
Joele Frank, Wilkinson Brimmer Katcher 
Eric Brielmann/Matt Cuneo 
212-355-4449

Industry leaders including Hewlett Packard, Kenwood, Sony, Robert Bosch, Philips, Nokia, DirecTV and Fujitsu are among the more than fifty global companies from the U.S., Japan, Korea, Taiwan and Europe that have purchased MMP Portfolio licenses.

About Royal Philips Electronics

Royal Philips Electronics of the Netherlands (NYSE: PHG) (AEX: PHI) is a global leader in healthcare, lighting and consumer lifestyle, delivering people-centric, innovative products, services and solutions through the brand promise of "sense and simplicity." Headquartered in the Netherlands, Philips employs approximately 123,800 employees in more than 60 countries worldwide. With sales of EUR 27 billion in 2007, the company is a market leader in medical diagnostic imaging and patient monitoring systems, energy efficient lighting solutions as well as lifestyle solutions for personal wellbeing. News from Philips is located at www.philips.com/newscenter.

About the MMP Portfolio

The Moore Microprocessor Patent Portfolio contains intellectual property that is jointly owned by the privately-held TPL Group and publicly-held Patriot Scientific Corporation (OTCBB: PTSC). The MMP Portfolio includes seven U.S. patents as well as their European and Japanese counterparts. It is widely recognized that the MMP Portfolio protects fundamental technology used in microprocessors, microcontrollers, digital signal processors (DSPs), embedded processors and system-on-chip (SoC) devices. Manufacturers of microprocessor-based products can learn more about how to participate in the MMP Portfolio Licensing Program by contacting: mmp-licensing@alliacense.com.

About Patriot Scientific Corporation

Headquartered in Carlsbad, California, Patriot Scientific Corporation is a leading intellectual-property licensing company that developed key microprocessor technologies used in myriad wireless devices, smart cards, home appliances, network gateways, set-top boxes, entertainment technology, automotive telematics, biomedical devices, industrial controllers and more. Patriot Scientific has recently embarked on an aggressive business expansion initiative based on selective expansion of its IP portfolio, minority investments in early-stage technology companies and full M&A. For more information on Patriot Scientific Corporation, visit: www.ptsc.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, patent litigation, technical development risks, seasonality and other risk factors detailed in the company's Securities and Exchange Commission filings.

SOURCE: Patriot Scientific Corporation

Patriot Scientific Corporation 
Angela Hartley, 760-547-2700 ext. 102

Lighting Science Group Corporation (www.lsgc.com) innovates, designs, manufactures and markets LED lighting solutions for professional and consumer applications that are environmentally friendlier and less costly to operate than traditional lighting products. The Company's patented and patent-pending designs in power management, thermal management, light engines, controls and micro-electronics are engineered to enhance lighting performance, reduce energy consumption, lower maintenance costs and eliminate the use of hazardous materials. The company is at the forefront of global LED research and product development and designs and manufactures ready-to-use LED lamps and luminaires, as well as provides customized lighting solutions for architectural and artistic projects. Lighting Science has offices in New York, New York; Westampton, New Jersey; Sacramento, California; Satellite Beach, Florida; Dallas, Texas; Tokyo, Japan; Goes, The Netherlands; Buckinghamshire, England; and Sydney, Australia.

About LED Holdings

LED Holdings, LLC, a portfolio company of Pegasus Capital Advisors (www.pcalp.com) holds a majority of the issued and outstanding shares of Common Stock of Lighting Science Group Corporation. Pegasus Capital Advisors is a private equity fund manager with offices in New York, New York and Cos Cob, Connecticut. Founded in 1995, Pegasus provides capital to middle market companies across a wide range of industries, with particular focus on businesses that make a meaningful contribution to society by positively affecting the environment, contributing to sustainability and enabling healthy living.

SOURCE Lighting Science Group Corporation

http://www.lsgc.com

Amalga HIS is built around an electronic health record (EHR) and includes complete patient and bed management as well as an integrated radiology information system (RIS) and a picture archiving and communication system (PACS).

"Ensuring seamless information sharing across the enterprise requires that input from various departments and sources, such as medical notes, discharge summaries or ward visits, is captured and stored in a standardized format. SpeechMagic's advanced technology and ongoing research in the field of semantic interoperability will allow us to quickly bring advanced information capture to Amalga HIS and Amalga RIS/PACS customers around the globe," said Steve Shihadeh, vice president, Microsoft Health Solutions Group.

Microsoft Health Solutions Group and Philips Speech Recognition Systems will immediately start the process of integrating their technologies.

About Royal Philips Electronics

Royal Philips Electronics of the Netherlands (NYSE:PHG)(AEX:PHI) is a diversified Health and Well-being company, focused on improving people's lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 133,000 employees in more than 60 countries worldwide. With sales of EUR 27 billion in 2007, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.

SOURCE: Royal Philips Electronics

Philips Speech Recognition Systems 
Anne Durand-Badel, +43 1 601 01 1048 
anne.durand-badel@philips.com 
www.philips.com/speechrecognition